Table 19 Medication and agent groups for CKD with T2DM compared to [5]
| Â | Overall | No CKD | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 |
|---|---|---|---|---|---|---|---|
n | Â | Â | Â | Â | Â | Â | Â |
Paper | 1380 | 1122 | 144 | 159 | 258 | 32 | 16 |
UKW | 35636 | 20314 | 34 | 4725 | 7659 | 1671 | 1603 |
Med1 | 13461 | 6452 | * | 2264 | 3319 | 735 | 766 |
DM medication | Â | Â | Â | Â | Â | Â | Â |
Paper | 83% | 81% | 84% | 89% | 84% | 94% | 77% |
UKW | 60% | 59% | 59% | 69% | 62% | 55% | 44% |
Med1 | 71% | 69% | * | 79% | 72% | 69% | 61% |
Insulin | Â | Â | Â | Â | Â | Â | Â |
Paper | 19% | 15% | 16% | 28% | 24% | 38% | 63% |
UKW | 26% | 24% | 24% | 23% | 30% | 38% | 35% |
Med1 | 38% | 39% | * | 28% | 39% | 52% | 51% |
Oral antidiabetes medication | Â | Â | Â | Â | Â | Â | Â |
Paper | 75% | 75% | 81% | 77% | 72% | 69% | 44% |
UKW | 46% | 47% | 41% | 59% | 46% | 28% | 13% |
Med1 | 51% | 50% | * | 69% | 52% | 31% | 16% |
Biguanides | Â | Â | Â | Â | Â | Â | Â |
Paper | 56% | 62% | 68% | 55% | 36% | 4% | 3% |
UKW | 32% | 34% | 26% | 48% | 27% | 7% | 1% |
Med1 | 34% | 33% | * | 57% | 32% | 6% | 0% |
Sulfonylureas | Â | Â | Â | Â | Â | Â | Â |
Paper | 35% | 31% | 44% | 42% | 42% | 56% | 15% |
UKW | 8% | 7% | 9% | 10% | 10% | 7% | 2% |
Med1 | 7% | 6% | * | 11% | 9% | 7% | 2% |
DPP-4 inhibitors | Â | Â | Â | Â | Â | Â | Â |
Paper | 7% | 7% | 4% | 8% | 8% | 23% | 7% |
UKW | 12% | 11% | 24% | 14% | 17% | 13% | 7% |
Med1 | 17% | 15% | * | 19% | 20% | 17% | 10% |